NCLAT allows appeal and quashes NCLT order that found oppression in Acharya Laboratories' affairs.
Parties reach settlement where company will buy back respondent's 6.4% shares at fair value.
Original NCLT order had directed share purchase at fair value as of March 2022 with 8% interest.
Dispute centered on amendments to Articles of Association and a rights issue in March 2022.